Recommended Dose: 44 mcg given 3 times weekly by SC injection.
Rebif 22 mcg, also given 3 times weekly by SC injection, is recommended for patients who cannot tolerate the higher dose in view of the treating specialist.
Treatment should be initiated under supervision of a physician experienced in the treatment of the disease.
When first starting treatment with Rebif, in order to allow tachyphylaxis to develop thus reducing adverse reactions, it is recommended that 8.8 mcg (0.1 mL of Rebif 44 mcg or 0.2 mL of Rebif 22 mcg) be administered during the initial 2 weeks of therapy, 22 mcg (0.25 mL of Rebif 44 mcg or the total of Rebif 22 mcg) be administered in weeks 3 and 4, and the total of Rebif 44 mcg be administered from the 5th week onwards.
Children and Adolescents: No formal clinical trials or pharmacokinetic studies have been conducted in children or adolescents. However, limited published data suggest that the safety profile in adolescents 12-16 years receiving Rebif 22 mcg SC 3 times weekly is similar to that seen in adults. There is very limited information on the use of Rebif in children <12 years and therefore, Rebif should not be used in this population.
Prior to injection and for an additional 24 hrs after each injection, an antipyretic analgesic is advised to decrease flu-like symptoms associated with Rebif administration.
At the present time, it is not known for how long patients should be treated. Safety and efficacy with Rebif have not been demonstrated beyond 4 years of treatment. It is recommended that patients should be evaluated at least every 2nd year in the 4-year period after initiation of treatment with Rebif and a decision for longer-term treatment should then be made on an individual basis by the treating physician.